Ambulatory oxygen in interstitial lung disease
نویسندگان
چکیده
منابع مشابه
Ambulatory oxygen in interstitial lung disease.
The patient’s clinical situation was characterised by a normal pulmonary pressure and a transient need for oxygen supplementation; only low doses of oral prednisone were required. Presently, it is not possible to predict the patient’s clinical course, as no other similar cases have been reported. Lung transplantation currently represents the only treatment option for this disease, but it is hop...
متن کاملOxygen therapy for interstitial lung disease: a systematic review.
This review aims to establish the impact of oxygen therapy on dyspnoea, health-related quality of life (HRQoL), exercise capacity and mortality in interstitial lung disease (ILD).We included studies that compared oxygen therapy to no oxygen therapy in adults with ILD. No limitations were placed on study design or intervention type. Two reviewers independently evaluated studies for inclusion, as...
متن کاملThe Assessment of Health-Related Quality of Life in Scleroderma-Interstitial Lung Disease
Introduction: Pulmonary involvement is the most common cause of mortality and disability in patients with systemic sclerosis and it significantly affects the quality of life in these patients. Therefore, early diagnosis and treatment of pulmonary involvement seems necessary in patients with SSc. In this study, we aimed to assess the health-related quality of life (HRQoL) in patients with Sclero...
متن کاملInherited interstitial lung disease.
This article focuses on recent advances in the identification of genes and genetic polymorphisms that have been implicated in the development of human interstitial lung diseases. It focuses on the inherited mendelian diseases in which pulmonary fibrosis is part of the clinical phenotype and the genetics of familial idiopathic pulmonary fibrosis and other rare inherited interstitial lung disease...
متن کامل[Interstitial lung disease].
This concise article summarizes recent advances in the field of interstitial lung disease (ILD) with particular focus on clinically relevant findings. As a novel treatment option for idiopathic pulmonary fibrosis (IPF), pirfenidone has been granted marketing authorization in the European Union for the treatment of mild to moderate IPF. In contrast, the FDA refused to approve pirfenidone for the...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Respiratory Journal
سال: 2011
ISSN: 0903-1936,1399-3003
DOI: 10.1183/09031936.00190710